697 reports of this reaction
2.8% of all BIMEKIZUMAB reports
#8 most reported adverse reaction
CONDITION AGGRAVATED is the #8 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 697 FDA adverse event reports linking BIMEKIZUMAB to CONDITION AGGRAVATED. This represents approximately 2.8% of all 25,281 adverse event reports for this drug.
Patients taking BIMEKIZUMAB who experience condition aggravated should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONDITION AGGRAVATED is a less commonly reported adverse event for BIMEKIZUMAB, but still significant enough to appear in the safety profile.
In addition to condition aggravated, the following adverse reactions have been reported for BIMEKIZUMAB:
The following drugs have also been linked to condition aggravated in FDA adverse event reports:
CONDITION AGGRAVATED has been reported as an adverse event in 697 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONDITION AGGRAVATED accounts for approximately 2.8% of all adverse event reports for BIMEKIZUMAB, making it a notable side effect.
If you experience condition aggravated while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.